医药产业链数据库之：零售药房经营数据，2024年8-9月实体药店门店销售持续环比改善

Industry Investment Rating - Leading Market-A, maintaining the rating [3] Core Viewpoints - The sales performance of physical pharmacies has shown continuous month-on-month improvement from August to September 2024, driven by policy stimulus and consumption recovery [1][2] - The retail pharmacy industry is experiencing a slowdown in growth, but leading pharmacy chains are expected to achieve steady performance growth through optimized store structures and expansion [3][17][19] Macro Perspective - Industry Data - In 2023, the national retail pharmacy market size reached 6226 billion yuan, with a year-on-year growth rate of 1.8%, indicating a slowdown in growth due to intensified competition, reduced personal medical insurance account income, and diversion of demand to other channels [9][10] - From August to September 2024, the average daily sales per store for physical pharmacies were 2754.8 yuan and 2832.1 yuan, respectively, showing month-on-month growth of 2.2% and 2.8% [2][13] - The average number of orders per store in August and September 2024 were 40.19 and 41.16, respectively, with year-on-year and month-on-month growth rates of 3.3% and 2.4% [2][13] - The average customer spending per transaction remained stable at 68.5 yuan and 68.8 yuan in August and September 2024, respectively [2][13] - In the 38th week of 2024 (September 22-24), the average daily sales per store were 2953.80 yuan, a month-on-month increase of 2.11%, with the average number of orders per store at 43.06, a month-on-month increase of 2.45%, and stable customer spending per transaction at 68.6 yuan [2][15] Micro Perspective - Listed Pharmacy Companies - The market concentration of the retail pharmacy industry remains low, with the top six listed pharmacy companies accounting for only 16.68% of the market share in 2023, indicating significant room for further consolidation [17] - From 2020 to 2023, the compound growth rates of the retail pharmacy industry and the top six listed pharmacy companies were 3.74% and 15.33%, respectively, highlighting the superior growth potential of listed companies [17] - The expansion of physical stores by listed pharmacy companies has gradually stabilized, with a high proportion of relatively new stores (2-3 years old) contributing to steady performance growth [19] - In the first half of 2024, the proportions of relatively new stores for Yifeng Pharmacy, Dashenlin, Lao Bai Xing, Yixintang, Jianzhijia, and Shuyu Civilian were 30%, 25%, 31%, 15%, 38%, and 35%, respectively [19]